ESTABLISHMENT LABS HOLDINGS INC. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that ESTABLISHMENT LABS HOLDINGS INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Dec 31, 2018 | $61.21M | Mar 20, 2019 |
| FY2018 | Dec 31, 2017 | $34.68M | Mar 20, 2019 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $211.08M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $166.03M | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $165.15M | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | $161.70M | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | $126.68M | Mar 4, 2024 |
| FY2022 | Dec 31, 2020 | $84.68M | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | $89.57M | Mar 1, 2022 |
| FY2019 | Dec 31, 2018 | $61.21M | Mar 16, 2020 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $146.31M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $109.53M | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $106.98M | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | $106.60M | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | $85.40M | Mar 4, 2024 |
| FY2022 | Dec 31, 2020 | $52.50M | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | $54.86M | Mar 1, 2022 |
| FY2019 | Dec 31, 2018 | $36.12M | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | $17.70M | Mar 20, 2019 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($51.06M) | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | ($84.60M) | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | ($78.50M) | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | ($75.21M) | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | ($41.14M) | Mar 4, 2024 |
| FY2022 | Dec 31, 2020 | ($38.12M) | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | ($38.15M) | Mar 1, 2022 |
| FY2019 | Dec 31, 2018 | ($21.10M) | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | ($34.90M) | Mar 20, 2019 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($39.01M) | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | ($49.99M) | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | ($65.03M) | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | ($39.66M) | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | ($25.14M) | Mar 4, 2024 |
| FY2022 | Dec 31, 2020 | ($27.92M) | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | ($30.94M) | Mar 1, 2022 |
| FY2019 | Dec 31, 2018 | ($23.86M) | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | ($19.98M) | Mar 20, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $20.25M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $19.71M | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $26.43M | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | $20.27M | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | $18.32M | Mar 4, 2024 |
| FY2022 | Dec 31, 2020 | $13.79M | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | $14.99M | Mar 1, 2022 |
| FY2019 | Dec 31, 2018 | $12.69M | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | $6.86M | Mar 20, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $165.07M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $139.81M | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $145.58M | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | $125.98M | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | $92.23M | Mar 4, 2024 |
| FY2022 | Dec 31, 2020 | $66.63M | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | $70.81M | Mar 1, 2022 |
| FY2019 | Dec 31, 2018 | $47.30M | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | $30.82M | Mar 20, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($50.89M) | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | ($58.52M) | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | ($88.51M) | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | ($52.17M) | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | ($27.53M) | Mar 4, 2024 |
| FY2022 | Dec 31, 2020 | ($12.51M) | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | ($29.98M) | Mar 1, 2022 |
| FY2019 | Dec 31, 2018 | ($33.89M) | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | ($31.97M) | Mar 20, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.05M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $6.11M | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $7.91M | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | $2.85M | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | $2.43M | Mar 4, 2024 |
| FY2022 | Dec 31, 2020 | $2.11M | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | $6.29M | Mar 1, 2022 |
| FY2019 | Dec 31, 2018 | $1.73M | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | $901.0K | Mar 20, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $357.17M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $346.83M | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | $268.64M | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | $211.06M | Mar 4, 2024 |
| FY2022 | Dec 31, 2021 | $139.53M | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | $156.39M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $116.53M | Mar 15, 2021 |
| FY2019 | Dec 31, 2018 | $116.57M | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | $57.10M | Mar 20, 2019 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $333.62M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $293.74M | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | $250.25M | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | $219.25M | Mar 4, 2024 |
| FY2022 | Dec 31, 2021 | $88.79M | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | $81.43M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $76.92M | Mar 15, 2021 |
| FY2019 | Dec 31, 2018 | $47.09M | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | $62.11M | Mar 20, 2019 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $23.55M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $53.10M | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $18.40M | Feb 27, 2026 |
| FY2025 | Dec 31, 2022 | ($8.19M) | Feb 27, 2026 |
| FY2024 | Dec 31, 2021 | $50.74M | Feb 28, 2025 |
| FY2023 | Dec 31, 2020 | $74.96M | Mar 4, 2024 |
| FY2022 | Dec 31, 2019 | $39.61M | Mar 1, 2023 |
| FY2021 | Dec 31, 2018 | $69.49M | Mar 1, 2022 |
| FY2019 | Dec 31, 2017 | ($5.01M) | Mar 16, 2020 |
| FY2018 | Dec 31, 2016 | ($26.44M) | Mar 20, 2019 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.21M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $1.21M | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | $465.0K | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | $465.0K | Mar 4, 2024 |
| FY2022 | Dec 31, 2021 | $465.0K | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | $465.0K | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $465.0K | Mar 15, 2021 |
| FY2019 | Dec 31, 2018 | $465.0K | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | $465.0K | Mar 20, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($495.76M) | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | ($444.69M) | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | ($360.10M) | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | ($281.59M) | Mar 4, 2024 |
| FY2022 | Dec 31, 2021 | ($206.39M) | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | ($165.25M) | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | ($127.13M) | Mar 15, 2021 |
| FY2019 | Dec 31, 2018 | ($88.98M) | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | ($67.88M) | Mar 20, 2019 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $75.57M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $90.35M | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | $40.04M | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | $66.36M | Mar 4, 2024 |
| FY2018 | Dec 31, 2018 | $52.64M | Mar 20, 2019 |
| FY2018 | Dec 31, 2017 | $10.86M | Mar 20, 2019 |
| FY2018 | Dec 31, 2016 | $479.0K | Mar 20, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $0 | Feb 28, 2025 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | (3) | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | (3) | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | (3) | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | (1) | Mar 4, 2024 |
| FY2022 | Dec 31, 2020 | (1) | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | (1) | Mar 1, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | (3) | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | (3) | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | (3) | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | (1) | Mar 4, 2024 |
| FY2022 | Dec 31, 2020 | (1) | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | (1) | Mar 1, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 29.30M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | 28.79M | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | 26.09M | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | 24.41M | Mar 4, 2024 |
| FY2022 | Dec 31, 2021 | 24.08M | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | 23.52M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | 20.65M | Mar 15, 2021 |
| FY2019 | Dec 31, 2018 | 20.26M | Mar 16, 2020 |